Sign In
Buy IMNN
$2.10
-0.0400 (-1.87%)
At Close: Jun 03, 2026
IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
08:05am, Thursday, 28'th Aug 2025
LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
04:00pm, Tuesday, 05'th Aug 2025
Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN),
Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript
01:26pm, Tuesday, 05'th Aug 2025
Imunon, Inc. (NASDAQ:IMNN ) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Company Participants Douglas V. Faller - Chief Medical Officer Khursheed Anwer - Executive VP & Chief Scientific
IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update
08:00am, Tuesday, 05'th Aug 2025
Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
08:05am, Wednesday, 30'th Jul 2025
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN),
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
08:30am, Tuesday, 29'th Jul 2025
LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company
IMUNON Announces Stock Dividend Boosting Shareholder Value
08:05am, Monday, 28'th Jul 2025
Stock Dividend Reflects Company's Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders
IMUNON Announces Reverse Stock Split
08:00am, Wednesday, 23'rd Jul 2025
LAWRENCEVILLE, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
08:05am, Tuesday, 15'th Jul 2025
Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-s
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
08:05am, Wednesday, 18'th Jun 2025
ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO
Clinical Data Highlight PlaCCine's Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
08:05am, Tuesday, 03'rd Jun 2025
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001's Ability to Recruit a Powerful Anti-Cancer Immune Response
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
08:05am, Monday, 02'nd Jun 2025
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
06:59pm, Friday, 23'rd May 2025
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
